tbuckley/cabot-search huggingface dataset:
Abstract P109: Lipid Accumulation Product (LAP) is Associated with Hepatic Steatosis Among Individuals without Metabolic Syndrome
Authors: Ebenezer T Oni, Oluseye Ogunmoroti, Michael Blaha, Arthur S Agatston, Roger S Blumenthal, Jose Carvalho, Raquel Conceiçao, Raul D Santos, Khurram Nasir
Journal: Circulation (2016)

Background: The Lipid accumulation product (LAP) is a simple index formulated to identify cardiometabolic disorders. It has been shown to be predictive of the metabolic syndrome (MS) and its associated risk. Hepatic steatosis (HS) is associated with cardiometabolic disorders and considered an independent risk factor for increased cardiovascular disease (CVD). We evaluated the association of LAP with HS is the presence and absence of MS in an asymptomatic population. Methods: We evaluated 6,464 asymptomatic Brazilian subjects (43±10 years, 79% males) between November 2008 and July 2010. LAP (waist-58 х triglycerides [nmol/L]) was divided into quartiles and HS was defined by abdominal sonogram. Results: The overall prevalence of HS was 36% (n=2,310). There was a steady increase in HS prevalence with LAP quartiles: Q1- 3%, Q2- 14%, Q3- 31%, Q4- 52, p&lt;0.001. Twenty percent had MS, 75% of whom were in the 4 th quartile of LAP. In a logistic regression analysis higher quartiles of LAP were independently associated with higher prevalent odds of HS. When stratified by the presence of MS, the association only remained significant among persons without MS. See Table below. Conclusions: In an asymptomatic population there is an association between the higher LAP index and Hepatic Steatosis in persons without the metabolic syndrome. LAP index may be a relevant tool in predicting and screening for HS in individuals without MS.
Resolution of Visual Dysphotopsias after Laser Iridotomy: Six-Month Follow-up
Authors: Srinivasan Kavitha, Pradeep Y. Ramulu, Rengaraj Venkatesh, Krishnamurthy Palaniswamy, Mohideen Abdul Kader, Ganesh V. Raman, Sharmila Rajendrababu, Nazlee Zebardast
Journal: Ophthalmology (2018)
Abstract 19764: Impact of Chronic Kidney Dysfunction Among Patients With Stable Coronary Artery Disease: Ten-Year Follow-Up of Mass II Trial
Authors: Eduardo G Lima, Whady Hueb, Cibele L Garzillo, Desiderio Favarato, Alexandre C Hueb, Paulo C Rezende, Expedito E Silva, Rosa M Garcia, Thiago L Scudeler, Jose A Ramires, Roberto Kalil Filho
Journal: Circulation (2016)

Introduction: Chronic kidney disease (CKD) has poor prognosis among patients with stable coronary artery disease (CAD), but there is a lack of evidence regarding long term follow-up. Our objective was to evaluate the CKD in patients with multivesselCAD preserved ventricular function, and the interaction betweenreceived treatment and mortality in a 10-year follow-up. Hypothesis: CKD level would interact with treatment options regarding mortality. Methods: The glomerular filtration rate was determined at baseline on 611 patients who were randomized intothree treatment groups: medical treatment (MT), percutaneous coronary intervention (PCI), and coronary artery bypass surgery (CABG). Endpoint considered was overall death.Survival was estimated by the Kaplan-Meier method and hazard ratio (HR) using Cox proportional hazard. Results: Of 611 patients, 112 (18%) had normal renal function, 349 (57%) mild dysfunction, and 150 (25%) moderate dysfunction. Treatment assigned and baseline characteristicswere similar am...
The Third Postmastectomy Reconstruction Option—Autologous Fat Transfer
Authors: Kimberly S. Khouri, Roger K. Khouri, Roger K. Khouri
Journal: JAMA Surgery (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
A Novel FES Strategy for Poststroke Rehabilitation Based on the Natural Organization of Neuromuscular Control
Authors: Vincent C. K. Cheung, Chuanxin M. Niu, Si Li, Qing Xie, Ning Lan
Journal: IEEE Reviews in Biomedical Engineering (2018)

The past decades have witnessed remarkable progress in neural technologies such as functional electrical stimulation (FES) and their applications in neurorehabilitation and neuromodulation. These advances are powered by new neuroscientific understandings of the organization and compositionality of neuromuscular control illuminating how muscle groups may be activated together as discrete units known as muscle synergies. These parallel developments have promoted novel approaches to clinical rehabilitation for neurological disorders that are insurmountable to current treatments. One such breakthrough is the evolution of FES as a therapeutic tool in poststroke rehabilitation with an interventional strategy particularly inspired by the concept that muscles in humans may be purposefully coordinated through neuromotor modules represented as muscle synergies. This paper will review recent advances in multichannel FES technology, its potential applications in poststroke rehabilitation, new findings that support the neurological basis of the muscle synergies for generating natural motor tasks, and the application of the muscle-synergy concept in poststroke assessment and rehabilitation of motor impairment. Finally, we will recommend future directions of development in relation to assistive FES and synergy-driven adaptive training for poststroke rehabilitation.
GW29-e1001 The use of P2Y12 inhibitors in ACS patients with culprit lesion of left main disease in China: findings from the CCC-ACS Project
Authors: Guanqi Zhao, Jing Liu, Na Yang, Gregg C. Fonarow, Junbo Ge, Kathryn A. Taubert, Louise Morgan, Changsheng Ma, Dong Zhao, Yaling Han, Sidney C. Smith, Yong Huo, Shaoping Nie
Journal: Journal of the American College of Cardiology (2018)
Safety and effectiveness of pembrolizumab monotherapy in NSCLC: Interim analysis of Japan postmarketing surveillance
Authors: Terufumi Kato, Nobuyuki Yamamoto, Masahiko Ozaki, Masahiro Hamada, Tomoko Yamada, Tetsu Kamitani, Yoshiko Kawakami, Yuichiro Ito, Mitsuyoshi Hara
Journal: Annals of Oncology (2018)
Abstract 16593: Risk of Intracranial Hemorrhage During Warfarin Therapy in Patients With Atrial Fibrillation - Insights From the FinWAF Registry
Authors: Mika Lehto, Paula Tiili, Jukka Putaala, Jussi Niiranen, Pasi Korhonen, Juha Mehtälä, Riitta Lassila, Pekka Raatikainen
Journal: Circulation (2016)

Background: The risk of stroke in patients with atrial fibrillation (AF) is reduced with oral anticoagulation therapy (OAT). On the other hand, OAT with warfarin increases the risk of intracranial hemorrhage (ICH). In this nationwide registry study we evaluated the association between the quality of warfarin therapy and the risk of ICH. Methods: FinWAF is a registry study of 54568 unselected AF patients (31172 prevalent and 23396 new warfarin users) by linking data from several Finnish nationwide registries through the civil registration number. Crude incidence rates of ICH among patients with various time in therapeutic range (TTR) levels were analyzed. TTR was assessed with the Rosendaal method and analyzed with a continuous calculation window of 60 days. Hazard ratios (HR) for ICH were adjusted for age, gender, congestive heart failure, hypertension, diabetes, previous stroke, transient ischemic attack, vascular disease, hospitalization and renal function. Results: The mean follow-up time was 3.2 ± 1.6...
eXalt3: Phase III randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase positive non-small cell lung cancer patients
Authors: L. Horn, Y.-L. Wu, M. Reck, H. Wakelee, C. Liang, K. Harrow, V. Oertel, T. Mok
Journal: Annals of Oncology (2018)
University of Melbourne: combining practice with innovation in the latest completely online Masters of Sports Medicine (continuing professional development series)
Authors: Dominic Mah
Journal: British Journal of Sports Medicine (2018)

Faculty of Medicine, Dentistry & Health Sciences, The University of Melbourne, Melbourne, Australia.

Masters of Sports Medicine.

Delivered 100% online, the newly released Masters of Sports Medicine at the University of Melbourne targets clinicians looking to develop a successful sports and exercise medicine (SEM) career. Such postgraduate qualifications open doors as an SEM professional with recognised expertise, as well as providing stepping stones towards final-stage specialty training.1–4 

Launched in 2018, this is Australia’s latest postgraduate SEM programme. It is designed for medical doctors, physiotherapists and podiatrists worldwide with ≥3 years of sports-relevant clinical experience (table 1), seeking to extend expertise in all areas of SEM including physical activity, community participation and high-performance sport. The programme is directed by Sonya …
Gastroenteropancreatic Neuroendocrine Tumors
Authors: Mauro Cives, Jonathan R. Strosberg
Journal: CA A Cancer Journal for Clinicians (2018)

Abstract Neuroendocrine tumors (NETs) are heterogeneous malignancies arising from the diffuse neuroendocrine system. They frequently originate in the gastroenteropancreatic (GEP) tract and the bronchopulmonary tree, and their incidence has steadily increased in the last 3 decades. Fundamental biologic and genomic differences underlie the clinical heterogeneity of NETs, and distinct molecular features characterize NETs of different grades and different primary sites. Although surgery remains the cornerstone of treatment for localized tumors, systemic treatment options for patients with metastatic NETs have expanded considerably. Somatostatin analogs have demonstrated both antisecretory and antitumor efficacy. Peptide receptor radionuclide therapy with lutetium‐177 dotatate ( 177 Lu‐DOTATATE) has been approved for advanced GEP‐NETs. The antitumor activity of everolimus has been demonstrated across a wide spectrum of NETs, and the antiangiogenic agent sunitinib has been approved for pancreatic NETs (pNETs). Chemotherapy with temozolomide and capecitabine has recently demonstrated an unprecedented prolongation of progression‐free survival in a randomized trial of pNETs. Multiple retrospective series have reported the efficacy of liver‐directed therapies both for palliating symptoms of hormone excess and for controlling tumor growth. Telotristat, an oral inhibitor of tryptophan hydroxylase, has been shown to reduce diarrhea in patients with carcinoid syndrome. Defining the therapeutic algorithm and identifying biomarkers predictive of response to treatments are among the main priorities for the next decade of research in the NET field.
GW29-e1996 Long noncoding RNA CTB-41I6.2 positively regulates LPS-induced IL6 expression in monocytes
Authors: Yuanfeng Gao, Chenyi Xue, Jianting Shi, Daniel Y. Li, Jane F. Ferguson, Muredach P. Reilly, Xinchun Yang, Hanrui Zhang
Journal: Journal of the American College of Cardiology (2018)
A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (rhabdoid tumor cohort) (NCT02601950)
Authors: R.L. Jones, J.-Y. Blay, M. Agulnik, R. Chugh, O. Mir, A. Italiano, D. Thomas, A. Gupta, T. Jahan, G. Cote, V. Villalobos, G.D.D. Demetri, M. Roche, I. Sapir, S. Daigle, A. Clawson, M. Gounder
Journal: Annals of Oncology (2018)
Quality of life in patients with soft tissue sarcoma undergoing palliative treatment: A multicenter, cluster-randomized trial within the Germany Interdisciplinary Sarcoma Group (GISG-12)
Authors: L. Hentschel, S. Richter, H.-G. Kopp, B. Kasper, A. Kunitz, V. Grünwald, T. Kessler, J.-M. Chemnitz, U. Pelzer, U.S. Schuler, J. Freitag, A. Schilling, B. Hornemann, K. Arndt, G. Ehninger, M. Bornhäuser, M. Schuler
Journal: Annals of Oncology (2018)
Deamidation of Amino Acids on the Surface of Adeno-Associated Virus Capsids Leads to Charge Heterogeneity and Altered Vector Function
Authors: April R. Giles, Joshua J. Sims, Kevin B. Turner, Lakshmanan Govindasamy, Mauricio R. Alvira, Martin Lock, James M. Wilson
Journal: Molecular Therapy (2018)

Post-translational modification of the adeno-associated virus capsids is a poorly understood factor in the development of these viral vectors into pharmaceutical products. Here we report the extensive capsid deamidation of adeno-associated virus serotype 8 and seven other diverse adeno-associated virus serotypes, with supporting evidence from structural, biochemical, and mass spectrometry approaches. The extent of deamidation at each site depended on the vector's age and multiple primary-sequence and three-dimensional structural factors. However, the extent of deamidation was largely independent of the vector recovery and purification conditions. We demonstrate the potential for deamidation to impact transduction activity and, moreover, correlate an early time point loss in vector activity to rapidly progressing spontaneous deamidation at several adeno-associated virus 8 asparagines. We explore mutational strategies that stabilize side-chain amides, improving vector transduction and reducing the lot-to-lot molecular variability that presents a key concern in biologics manufacturing. This study illuminates a previously unknown aspect of adeno-associated virus capsid heterogeneity and highlights its importance in the development of these vectors for gene therapy. Post-translational modification of the adeno-associated virus capsids is a poorly understood factor in the development of these viral vectors into pharmaceutical products. Here we report the extensive capsid deamidation of adeno-associated virus serotype 8 and seven other diverse adeno-associated virus serotypes, with supporting evidence from structural, biochemical, and mass spectrometry approaches. The extent of deamidation at each site depended on the vector's age and multiple primary-sequence and three-dimensional structural factors. However, the extent of deamidation was largely independent of the vector recovery and purification conditions. We demonstrate the potential for deamidation to impact transduction activity and, moreover, correlate an early time point loss in vector activity to rapidly progressing spontaneous deamidation at several adeno-associated virus 8 asparagines. We explore mutational strategies that stabilize side-chain amides, improving vector transduction and reducing the lot-to-lot molecular variability that presents a key concern in biologics manufacturing. This study illuminates a previously unknown aspect of adeno-associated virus capsid heterogeneity and highlights its importance in the development of these vectors for gene therapy.
Abstract 16521: Assessment of Risk in Patients Undergoing Aortic Surgery After Prior Coronary Artery Bypass Grafting
Authors: Ourania Preventza, Erin M Corsini, Matt D Price, Muhammad Aftab, Subhasis Chatterjee, Lorraine D Cornwell, Shuab Omer, Ernesto Jimenez, Kim I de la Cruz, Ravi K Ghanta, Arin C Jobe, Joseph S Coselli
Journal: Circulation (2017)

Introduction: Aortic arch surgery is a high-risk procedure for patients who have previously undergone coronary artery bypass grafting (CABG). The aim of our study was to assess the risk and determi...
Phase Ib/II study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who had progressive disease on or after prior anti-PD-1 therapy
Authors: A. Ribas, I. Mehmi, T. Medina, C. Lao, S. Kummar, A. Amin, S. Deva, A.K. Salama, T. Tueting, M. Milhem, C.J. Hoimes, G. Daniels, M. Shaheen, S. Jang, M. Barve, A. Powell, S. Chandra, E.V. Schmidt, R. Janssen, G.V. Long
Journal: Annals of Oncology (2018)
High Intratumoral Galectin-1 Is Associated with Adverse Outcome in ALK-Negative, CD30-Positive Peripheral T-Cell Lymphomas
Authors: Johanne Marie Holst, Maja Ludvigsen, Stephen Jacques Hamilton Dutoit, Knud Bendix, Trine Lindhardt Plesner, Peter Nørgaard, Michael Boe Møller, Torben Steiniche, Gabriel A Rabinovich, Francesco Annibale d'Amore, Martin Bjerregård Pedersen
Journal: Blood (2017)
Abstract 18904: VARSITY Study (VA Retrospective study of Statin IntensiTY): Utilizing a Large VA Cohort to Determine the Actual Clinical Response of LDL Reduction After Initiating Statin Therapy in Newly Diagnosed ASCVD
Authors: Mark Garcia, Allison Murata, Gerald Charlton
Journal: Circulation (2015)

Background: According to the 2013 ACC/AHA Blood Cholesterol Guideline (BCGL), high-intensity statin therapy (HIST) is recommended in individuals with newly diagnosed atherosclerotic cardiovascular disease (ASCVD) and this therapy is expected to lower LDL by &gt;50%. These recommendations come from multiple studies which demonstrated that the reduction in major vascular events was proportional to the absolute LDL reduction. This retrospective study utilized a large VA cohort to report the LDL reduction with the initiation of statin therapy after an initial diagnosis of ASCVD. Methods: A national cohort of VA patients with a new diagnosis of ASCVD and subsequent initiation of statin therapy was constructed. The most proximate LDL measured within 12 weeks before (PreLDL) and 4-12 weeks after (PostLDL) initiation of statin therapy were recorded. Patients with a prior diagnosis of ASCVD, a prior prescription for any lipid lowering drug, or a prior prescription for immunosuppressant agents were excluded. The statin doses were categorized as high-, moderate- or low-intensity as defined in the 2013 BCGL. Results: This cohort consisted of 92,755 VA patients with an initial ASCVD diagnosis from 5/1992 to 7/2014. The cohort was 97% male, 19% ethnic minority, and the average age was 66.7 (± 10.9) years. The average PreLDL was 129.8 (±35.1), the average PostLDL was 94.2 (±31.7) mg/dl, and only 2.5% were prescribed HIST. The results are summarized in Table 1. Conclusion: This cohort study examined statin intensity and LDL reduction after the initial diagnosis of ASCVD. HIST was rarely prescribed as initial therapy and in a majority of these patients the expected &gt;50% LDL reduction was not achieved. This study suggests the need for additional research to explore the factors contributing to a &gt;50% reduction in LDL following the initiation of statin therapy in patients with ASCVD, and that the monitoring of response to HIST may be clinically important.
Efficiacy of C1-inhibitor plasma concentrate, the main kallikrein inactivator, in preventing hyperamylasemia induced by endoscopic papillosphincterotomy
Authors: P. A. Testoni, M. Cicardi, L. Bergamaschini, S. Guzzoni, R. Castelli, M. Cugno, M. Buizza, A. Agostoni
Journal: Endoscopy (1993)
Abstract P006: A Population-based Approach to Sudden Unexpected Death Epidemiology
Authors: Chani J Hodonsky, Irion W Pursell, Sarah Chen, Carter Devlin, J. P Mounsey, Ross J Simpson
Journal: Circulation (2016)

Introduction: Sudden cardiac death accounts for 150,000 to 400,000 deaths in the United States annually. Published studies of sudden death use restrictive inclusion criteria such as timing of death, death-certificate disease attribution, hospital transport, attempted resuscitation, and victim survival status. These case definitions may undercount minority victims, victims who are socially isolated, or victims with limited healthcare access, leading to mischaracterization of sudden death in the general population. The SUDDEN study is a population-based epidemiologic analysis of out-of-hospital sudden unexpected death (OHSUD) in North Carolina that aims to characterize OHSUD incidence in the general population and identify associated risk factors. Methods: Wake County, North Carolina, is a predominantly urban county with approximately 4,700 adult deaths in a 2013 population of 974,289. All possible sudden unexpected deaths over one year in Wake County were collected via EMS. Death certificates, medical records, and post mortem examination data were used to determine demographic information and comorbidities. Of 1,138 18- to 64 year olds identified as possible OHSUD victims, 187 cases were adjudicated into the study population. Population-based estimates were age- and sex-standardized to 2013 North Carolina mortality tables to estimate a statewide OHSUD count. Results: Out-of-hospital sudden unexpected death accounted for approximately 14% of all deaths in adults under age 65. Up to 13.5% of all 2013 Wake County deaths outside of a healthcare institution were attributable to OHSUD. Approximately 2/3 of SUDDEN cases would have been excluded by timing criteria in commonly used sudden death case definitions. Hypertension, ischemic heart disease, hypercholesterolemia, COPD, and diabetes were all highly prevalent in Wake County OHSUD victims. OHSUD accounted for 48% of deaths in 18- to 64-year-olds with diseases of the heart, stroke/cerebrovascular disease, or chronic lower respiratory disease listed as the cause of death. 52% of all 2013 OHSUD in Wake County listed a cardiac primary cause on the death certificate; 37% were listed as having non-cardiac causes, with the remaining listing an unknown or a non-natural cause (e.g., trauma). Excluding non-cardiac causes of death would misclassify over 1,500 OHSUD victims per year in North Carolina alone. Discussion: Sudden death incidence estimates vary widely according to published exclusion criteria, leading to a mischaracterization of a disease that needs to be addressed on a national level. Restrictive exclusion criteria used in published studies of sudden death underestimate the incidence of OHSUD and divert resources from populations that would benefit the most from targeted interventions.
GW29-e0902 Prevalence and Clinical Implications of Newly Revealed, Asymptomatic Abnormal Ankle-Brachial Index in Patients With Significant Coronary Artery Disease — 7-Year Outcomes
Authors: Seung Jae Lee, Jong Young Lee, Seung Whan Lee, Woo Seok Lee, Seungbong Han, Yong Kyu Park, Chang Hee Kwon, Jeong Yoon Jang, Young Rak Cho, Gyung Min Park, Jung Min Ahn, Won Jang Kim, Duk Woo Park, Soo Jin Kang, Young Hak Kim, Cheol Whan Lee, Seong Wook Park, Seung Jung Park, Ki Chul Sung
Journal: Journal of the American College of Cardiology (2018)